Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis

Therapeutic Apheresis

Volumn 1, Issue 4, 1997, Pages 343-347

  Okada, Hirokazu ^a   Moriwaki, Kenshi ^a   Sugahara, Souichi ^a   Nakamoto, Hidetomo ^a   Hosokawa, Takeshi ^a   Hamaguchi, Katsuhiko ^a   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Double filtration plasmapheresis; Muscle strength; Myasthenia gravis; Plasma adsorption; Subjective symptoms

Indexed keywords

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MYASTHENIA GRAVIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 0031261158     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1997.tb00052.x     Document Type: Review

References (21)

1. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drugs therapy in myasthenia gravis. N Engl J Med 1997;297:1134-40.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1978;298: 136-42.
3. Lindstrom JM, Seybold ME, Lennon VA, Shittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-59.
4. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298: 1116-22.
5. Takamori M, Hamada T, Okumura S. Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: An approach to antigenic synthetic peptides. J Neurol Sci 1992;109:182-87.
6. Takamori M, Okumura S, Nagata M, Yoshikawa H. Myasthenogenic significance of synthetic alpha-subunit peptide 183-200 of Torpedo californlca and human acetylcholine receptor. J Neurol Sci 1988;85:121-9.
7. Bergamini L, Cocito D, Durelli L, Quattrocolo G. Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis. Muscle Nerve 1985;6:457-8.
8. Pinching AJ, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet 1976;2: 1373-6.
9. Seybold ME. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1987:584-7.
10. Yamazaki Z, Fujimori Y, Takahama T, Inoue N, Wada T, Kazama M, Morioka M, Abe T, Yamawaki N, Inagaki K. Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif Intern Organs 1982;28:318-23.
11. Agishi T, Kaneko I, Hasuo Y, Hayasaka Y, Sanaka T, Ota K, Amemiya H, Sugino N, Abe M, Ono T, Kawai S, Yamane T. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 1980;26:406-9.
12. Besinger UA, Toyka KV, Hoemberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: Longer-term correlation of binding and bungarotoxin blocking antobides against acetylcholine receptors with changes in disease activity. Neurology 1983;33:1983.
13. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exercise 1982;14:377-81.
14. Ichikawa M, Koh CS, Hata Y, Tohyama M, Tsuno T, Komiyama A. Immunoadsorption plasmapheresis for severe generalized myasthenia gravis. Arch Dis Child 1993;69:236-8.
15. Sato T, Ishigakiv Y, Komiya T, Tsuda H. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis. Ann NY Acad Sci 1988;540:554-6.
16. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:578-81.
17. Drachmen DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and clinical severity of myasthenia gravis. N Engl J Med 1982;307: 769-75.
18. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993;50:837-10.
19. Roses AD, Olanow CW, McAdams MW, Lane RJ. No direct correlation between serum antiacethylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology 1981;31:220-4.
20. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57: 843-6.
21. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: Clinical correlations. Autoimmunity 1995;20:99-104.